TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer

New analysis of the NOVA trial confirms clinical benefit from niraparib for patients with recurrent ovarian cancer. The benefit occurred both in patients with and in those without BRCA mutations.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news